x

Posted 28 February, 2024

BioSig Technologies, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:BSGM in a 8-K filed on 28 February, 2024.


  Kenneth L. Londoner resigned from his positions as director, executive chairman and chief executive officer of BioSig Technologies, Inc. (the "Company") and from any and all committees, offices, appointments, designations, responsibilities or other capacities related to the Company or any of its subsidiaries, effective as of the Effective Date.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of BioSig Technologies, Inc.
Health Care/Life Sciences • Medical Equipment/Supplies
BioSig Technologies, Inc. is a medical technology company, which engages in the development of a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of electrocardiographic and intra-cardiac signals. Its product PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intra-cardiac signals for patients undergoing electrophysiology procedures. The company was founded by Kenneth L. Londoner on February 24, 2009 and is headquartered in Westport. CT.
Market Cap
$5.79M
View Company Details
BioSig Technologies, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On February 27, 2024, the Board appointed former director, Frederick D. Hrkac as a director, president and principal executive officer of the Company, effective as of February 27, 2024 (the "Effective Date"), to serve for a term expiring at the next annual meeting of the Company's stockholders or until his successor is duly elected and qualified, or his earlier death, resignation or removal. There are no arrangements or understandings between Mr. Hrkac and any other person pursuant to which Mr. Hrkac was selected as a director. There are no transactions in which Mr. Hrkac has an interest requiring disclosure under item 404(a) of Regulation S-K.


Kenneth L. Londoner resigned from his positions as director, executive chairman and chief executive officer of BioSig Technologies, Inc. (the "Company") and from any and all committees, offices, appointments, designations, responsibilities or other capacities related to the Company or any of its subsidiaries, effective as of the Effective Date. Mr. Londoner's resignation was not the result of any disagreement regarding any matter relating to the Company's operations, policies or practices.